<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-38853" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Antiemetics, Selective 5-HT3 Antagonists</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Theriot</surname>
            <given-names>Jonathan</given-names>
          </name>
          <aff>HonorHealth Scottsdale Thompson Peak Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Wermuth</surname>
            <given-names>Harrison R.</given-names>
          </name>
          <aff>Michigan State University College of Human Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Ashurst</surname>
            <given-names>John V.</given-names>
          </name>
          <aff>Kingman Regional Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Jonathan Theriot declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Harrison Wermuth declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>John Ashurst declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>19</day>
          <month>4</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-38853.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Selective serotonin receptor (5-HT3) antagonists block serotonin, specifically targeting gastrointestinal (GI) vagal nerve terminals and the chemoreceptor trigger zone within the central nervous system. This blockade leads to antiemetic effects, making them invaluable in managing nausea and vomiting induced by chemotherapy, radiation therapy, and postoperative procedures. Understanding the indications, dosing, administration, and potential adverse events associated with 5-HT3 receptor antagonists is crucial for healthcare professionals across disciplines. This activity provides comprehensive insights into the pharmacological mechanism, pharmacokinetics, contraindications, precautions, monitoring strategies, and toxicity profiles of these agents, emphasizing the collaborative efforts of interdisciplinary healthcare teams in effectively preventing and treating nausea and vomiting.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify&#x000a0;the mechanism of action of 5-HT3 receptor antagonists.</p></list-item><list-item><p>Identify the approved indications for 5-HT3 receptor blockers.</p></list-item><list-item><p>Determine the potential adverse events associated with 5-HT3 receptor antagonists.</p></list-item><list-item><p>Develop&#x000a0;strategies for the interprofessional healthcare team to improve care coordination and communication to improve patient outcomes when using 5-HT3 receptor antagonists.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=38853&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=38853">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-38853.s2" sec-type="Indications">
        <title>Indications</title>
        <p>The 5-HT3 receptor antagonists available on the US market include dolasetron, granisetron, palonosetron, and ondansetron.<xref ref-type="bibr" rid="article-38853.r1">[1]</xref> Dolanestron, granisetron, and ondansetron are first-generation 5-HT3 receptor antagonists. Palonosetron is a second-generation 5-HT3 receptor antagonist.<xref ref-type="bibr" rid="article-38853.r2">[2]</xref> Tropisetron and ramosetron are not available in the US.<xref ref-type="bibr" rid="article-38853.r1">[1]</xref>&#x000a0;</p>
        <p>Serotonin binding to 5-HT3 receptors triggers nausea and vomiting.<xref ref-type="bibr" rid="article-38853.r3">[3]</xref>&#x000a0;Serotonin 5-hydroxytryptamine-3 (5-HT3) receptor antagonists exert their activity on receptors located peripherally on gastrointestinal (GI) vagal nerve terminals and centrally in the chemoreceptor trigger zone (CTZ).<xref ref-type="bibr" rid="article-38853.r4">[4]</xref>&#x000a0;</p>
        <p>Chemotherapy-induced nausea and vomiting (CINV) may be acute or delayed.<xref ref-type="bibr" rid="article-38853.r5">[5]</xref> Acute CINV usually starts within 2 hours of chemotherapy administration and may last up to 24 hours. Delayed CINV starts 24 hours or more and lasts up to 5 days after chemotherapy administration.<xref ref-type="bibr" rid="article-38853.r5">[5]</xref><xref ref-type="bibr" rid="article-38853.r6">[6]</xref> Breakthrough CINV starts 5 days after chemotherapy administration.<xref ref-type="bibr" rid="article-38853.r7">[7]</xref> Serotonin&#x000a0;can&#x000a0;trigger acute CINV.<xref ref-type="bibr" rid="article-38853.r5">[5]</xref> Therefore,&#x000a0;All 5-HT3 receptor antagonists are effective in preventing acute CINV.<xref ref-type="bibr" rid="article-38853.r8">[8]</xref> Other neurotransmitters may be involved in the pathophysiology of delayed CINV, which explains the limited efficacy of 5-HT3 receptor antagonists in preventing delayed CINV.<xref ref-type="bibr" rid="article-38853.r5">[5]</xref> However, ondansetron and palonosetron prevent delayed CINV in addition to acute CINV.<xref ref-type="bibr" rid="article-38853.r8">[8]</xref><xref ref-type="bibr" rid="article-38853.r9">[9]</xref> Palonosetron is more effective than ondansetron in preventing delayed CINV.<xref ref-type="bibr" rid="article-38853.r8">[8]</xref> Granisetron extended-release subcutaneous formulation is indicated for acute and delayed CINV.<xref ref-type="bibr" rid="article-38853.r10">[10]</xref> Granisetron extended-release subcutaneous formulation is associated with less unscheduled rescue hydration to treat breakthrough CINV compared to palonosetron.<xref ref-type="bibr" rid="article-38853.r11">[11]</xref></p>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <p>
<bold>Prevention of chemotherapy-induced nausea and vomiting and radiation-induced nausea and vomiting</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Dolanestron</p>
          </list-item>
          <list-item>
            <p>Granisetron</p>
          </list-item>
          <list-item>
            <p>Ondansetron</p>
          </list-item>
          <list-item>
            <p>Palonosetron&#x000a0;<xref ref-type="bibr" rid="article-38853.r1">[1]</xref></p>
          </list-item>
        </list>
        <p>The manufacturer's labeling for dolasetron, granisetron (excluding extended-release subcutaneous formulation), or ondansetron does not specify if the indication is to prevent acute or delayed CINV.<bold>&#x000a0;</bold>Palonosetron's manufacturer labeling specifies its indication to prevent acute and delayed CINV.<xref ref-type="bibr" rid="article-38853.r8">[8]</xref> Granisetron (extended-release subcutaneous) is indicated for the prevention of acute and delayed CINV.<xref ref-type="bibr" rid="article-38853.r11">[11]</xref><bold/></p>
        <p>
<bold>Prevention of postoperative nausea and vomiting</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Granisetron</p>
          </list-item>
          <list-item>
            <p>Ondansetron</p>
          </list-item>
          <list-item>
            <p>Palonosetron&#x000a0;<xref ref-type="bibr" rid="article-38853.r1">[1]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Off-label&#x000a0;Uses</bold>
</p>
        <p>Ondansetron is used to treat nausea and vomiting associated with pregnancy, but data to support its safety is limited.<xref ref-type="bibr" rid="article-38853.r12">[12]</xref> The risk of fetal cleft palate is increased 2-fold with the use of ondansetron in the first trimester.<xref ref-type="bibr" rid="article-38853.r13">[13]</xref></p>
      </sec>
      <sec id="article-38853.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Gastric irritation or cellular damage triggers the intestinal release of 5-HT, which binds to 5-HT3 receptors in the GI tract. The activation of the 5-HT3 receptors triggers nausea and vomiting.<xref ref-type="bibr" rid="article-38853.r1">[1]</xref> Serotonin 5-HT3 receptor antagonists inhibit the activation of the 5-HT3 receptors peripherally and centrally, resulting in antiemetic effects.<xref ref-type="bibr" rid="article-38853.r1">[1]</xref> Palonosetron has a higher binding affinity to the 5-HT3 receptors than the first-generation 5-HT3 receptor antagonists.<xref ref-type="bibr" rid="article-38853.r3">[3]</xref> Additional receptors that trigger nausea and vomiting include dopamine D2 receptors, muscarinic M1 cholinergic receptors, histamine H1 receptors, cannabinoid receptors, and neurokinin-1 (NK1) receptors. Therefore, 5-HT3 receptor antagonists do not treat all causes of emesis. Antiemetics with different mechanisms of action target the other receptors.<xref ref-type="bibr" rid="article-38853.r1">[1]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:&#x000a0;</bold>Ondansetron, granisetron, and dolasetron have a rapid and complete absorption following oral administration.<xref ref-type="bibr" rid="article-38853.r14">[14]</xref><xref ref-type="bibr" rid="article-38853.r15">[15]</xref><xref ref-type="bibr" rid="article-38853.r16">[16]</xref></p>
        <p><bold>Distribution:&#x000a0;</bold>Ondansetron has a wide volume of distribution and is about 70% bound to plasma proteins.<xref ref-type="bibr" rid="article-38853.r14">[14]</xref>&#x000a0;Granisetron has a high volume of distribution.<xref ref-type="bibr" rid="article-38853.r15">[15]</xref></p>
        <p><bold>Metabolism:&#x000a0;</bold>Different enzymes of the CYP-450 enzyme system metabolize each of the 5-HT3 receptor antagonists.<xref ref-type="bibr" rid="article-38853.r3">[3]</xref> Patients with high CYP2D6 enzyme activity are less responsive to 5-HT3 receptor antagonists. Ondansetron undergoes hepatic metabolism by CYP3A4, CYP2D6, and CYP1A2. Granisetron undergoes first-pass metabolism by CYP2D6.<xref ref-type="bibr" rid="article-38853.r3">[3]</xref> Ondansetron and granisetron have a bioavailability of 60%.<xref ref-type="bibr" rid="article-38853.r14">[14]</xref><xref ref-type="bibr" rid="article-38853.r15">[15]</xref> The bioavailability of ondansetron in cancer patients is slightly higher.<xref ref-type="bibr" rid="article-38853.r14">[14]</xref><xref ref-type="bibr" rid="article-38853.r15">[15]</xref>&#x000a0;Smoking induces the metabolism of granisetron.<xref ref-type="bibr" rid="article-38853.r17">[17]</xref>&#x000a0;Dolasetron is a prodrug that undergoes hepatic metabolism to an active metabolite, hydrodolasetron.<xref ref-type="bibr" rid="article-38853.r16">[16]</xref><xref ref-type="bibr" rid="article-38853.r18">[18]</xref> Hydrodolasetron undergoes metabolism by CYP 2D6.<xref ref-type="bibr" rid="article-38853.r3">[3]</xref>&#x000a0;Polanosetron undergoes hepatic metabolism and has a bioavailability of about 97% after oral administration.<xref ref-type="bibr" rid="article-38853.r19">[19]</xref></p>
        <p><bold>Elimination:&#x000a0;</bold>Ondansetron undergoes extensive hepatic metabolism to inactive metabolites.<xref ref-type="bibr" rid="article-38853.r14">[14]</xref> The elimination half-life for ondansetron is about 4 hours. Granisetron undergoes 12% renal excretion.<xref ref-type="bibr" rid="article-38853.r15">[15]</xref> The elimination half-life for granisetron is about 4 to 6 hours. Dolasetron has a half-life of less than 10 minutes, while hydrodolasetron has a half-life of about 7 hours.<xref ref-type="bibr" rid="article-38853.r3">[3]</xref> Unchanged dolasetron undergoes less than 1% excretion in the urine.<xref ref-type="bibr" rid="article-38853.r16">[16]</xref>&#x000a0;Polanosetron is longer acting than the first-generation 5-HT3 receptor antagonists and has an elimination half-life of about 40 hours.<xref ref-type="bibr" rid="article-38853.r19">[19]</xref><xref ref-type="bibr" rid="article-38853.r3">[3]</xref>&#x000a0;Polanosetron undergoes about 80% renal excretion, with 40% of the drug being excreted unchanged.</p>
      </sec>
      <sec id="article-38853.s4" sec-type="Administration">
        <title>Administration</title>
        <p>5-HT3 receptor antagonists come in various formulations, offering multiple administration routes.<xref ref-type="bibr" rid="article-38853.r20">[20]</xref> These include oral tablets, orally disintegrating tablets, oral soluble film, oral solution, intramuscular (IM) injection, intravenous (IV) injection, subcutaneous (SubQ) injection, and transdermal patch.<xref ref-type="bibr" rid="article-38853.r21">[21]</xref><xref ref-type="bibr" rid="article-38853.r22">[22]</xref> Palonosetron comes in an IV formulation. Ondansetron&#x000a0;is available&#x000a0;as oral tablets, orally disintegrating tablets, an oral solution, and IV and IM formulations. Dolasetron comes in an oral tablet and IV solution. Granisetron&#x000a0;is available&#x000a0;as an oral tablet, oral solution, transdermal patch, an IV formulation, and extended-release SubQ injection. The extended-release subcutaneous formulation of granisetron is long-acting and provides a therapeutic drug concentration for up to 5 days post-injection and is effective for delayed CINV, in addition to acute CINV.<xref ref-type="bibr" rid="article-38853.r10">[10]</xref></p>
        <p>Common dosing and administration regimens for adults&#x000a0;include, but are not limited to:</p>
        <list list-type="bullet">
          <list-item>
            <p>Ondansetron:&#x000a0;
<list list-type="bullet"><list-item><p>For nausea and vomiting prophylaxis, chemotherapy-related:
<list list-type="bullet"><list-item><p>IV: (moderately to highly emetogenic chemo): 0.15 mg/kg/dose (maximum 16 mg/dose) every 4 hours for 3 doses.<xref ref-type="bibr" rid="article-38853.r23">[23]</xref>&#x000a0;Treatment should be initiated&#x000a0;30 minutes before chemotherapy<italic toggle="yes">.</italic></p></list-item><list-item><p>PO: (highly emetogenic chemo): 24 mg once 30 minutes before chemotherapy; ODT dose forms should not be chewed or crushed<italic toggle="yes">.</italic></p></list-item><list-item><p>PO: (moderately emetogenic chemo): 8 mg every 8 hours for&#x000a0;2 doses, then 8 mg every 12 hours until&#x000a0;1 or&#x000a0;2 days&#x000a0;after chemotherapy completion. Chemotherapy should be started 30 minutes before. Again,&#x000a0;ODT dosage forms should not be cut, crushed, or chewed.</p></list-item></list>
</p></list-item><list-item><p>Nausea and vomiting prophylaxis, post-operative: 4 mg intramuscularly (IM) or intravenously (IV) for&#x000a0;1 dose.<xref ref-type="bibr" rid="article-38853.r24">[24]</xref></p></list-item><list-item><p>Nausea and vomiting prophylaxis, radiotherapy-related (total body): 8 mg PO for&#x000a0;1 dose, given 1 to 2 hours before each therapy fraction; ODT dosage forms should&#x000a0;not be cut,&#x000a0;crushed, or chewed.<xref ref-type="bibr" rid="article-38853.r25">[25]</xref></p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Granisetron:
<list list-type="bullet"><list-item><p>Nausea and vomiting prophylaxis, chemotherapy-related: 10 &#x003bc;g/kg IV 30 minutes before chemotherapy; oral dose within 1 hour before chemo. Alternately, 2 mg PO once or 1 mg PO every 12 hours for&#x000a0;2 doses.<xref ref-type="bibr" rid="article-38853.r15">[15]</xref>&#x000a0;Granisetron should only be administered on the days of chemotherapy<italic toggle="yes"/></p></list-item><list-item><p>Nausea and vomiting prophylaxis, radiotherapy-related: 2 mg orally for a single dose; treatment should be started within&#x000a0;1 hour of radiotherapy.<xref ref-type="bibr" rid="article-38853.r26">[26]</xref></p></list-item><list-item><p>Nausea and vomiting prophylaxis, post-operative: 5-20 &#x003bc;g/kg IV as a single dose administered at the end of surgery.<xref ref-type="bibr" rid="article-38853.r27">[27]</xref><italic toggle="yes"/></p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Palonosetron:
<list list-type="bullet"><list-item><p>Nausea and vomiting prevention, chemotherapy-related: 0.25 mg IV for&#x000a0;1 dose, started 30 minutes before chemotherapy.<xref ref-type="bibr" rid="article-38853.r28">[28]</xref></p></list-item><list-item><p>Nausea and vomiting prophylaxis, post-operative: 0.075 mg IV for a single dose, started immediately before anesthesia induction.<xref ref-type="bibr" rid="article-38853.r29">[29]</xref></p></list-item></list>
</p>
          </list-item>
        </list>
        <p>The American Society of Clinical Oncology (ASCO) guidelines suggest administering granisetron extended-release subcutaneous injection or granisetron transdermal patch to patients undergoing a multiday chemotherapy cycle instead of administering a 5-HT3 receptor antagonist each day of the multiday cycle.<xref ref-type="bibr" rid="article-38853.r30">[30]</xref></p>
        <p>
<bold>Special Patient Populations</bold>
</p>
        <p><bold>Hepatic impairment:&#x000a0;</bold>Ondansetron requires dosage adjustment in patients with severe hepatic impairment.<xref ref-type="bibr" rid="article-38853.r14">[14]</xref>&#x000a0;Palonosetron, dolasetron, and granisetron do not require a hepatic dosage adjustment</p>
        <p><bold>Renal adjustment:&#x000a0;</bold>Ondansetron, palonosetron, and dolasetron do not require renal dosage adjustment. Granisetron requires renal dosage adjustment and is contraindicated in patients with a creatinine clearance of less than 30 mL/min.</p>
        <p><bold>Pregnancy considerations:&#x000a0;</bold>Ondansetron for nausea and vomiting: 4 mg PO every 8 hours in pregnant women who are not dehydrated or 8 mg IV every 12 hours to be infused over 15 minutes.<xref ref-type="bibr" rid="article-38853.r31">[31]</xref></p>
        <p><bold>Older&#x000a0;patients:&#x000a0;</bold>Ondansetron does not require dosage adjustment in older adults.<xref ref-type="bibr" rid="article-38853.r14">[14]</xref></p>
      </sec>
      <sec id="article-38853.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>The serotonin 5-HT3 receptor antagonists share a similar safety and tolerability profile.<xref ref-type="bibr" rid="article-38853.r32">[32]</xref></p>
        <p>
<bold>Most Common Adverse Reactions&#x000a0;</bold>
<xref ref-type="bibr" rid="article-38853.r1">[1]</xref>
<xref ref-type="bibr" rid="article-38853.r33">[33]</xref>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Headache (9% to 27%)</p>
          </list-item>
          <list-item>
            <p>Fatigue (9% to 13%)</p>
          </list-item>
          <list-item>
            <p>Malaise (9% to 13%)</p>
          </list-item>
          <list-item>
            <p>Constipation (6% to 11%)</p>
          </list-item>
        </list>
        <p>
<bold>One Percent to 10%</bold>
</p>
        <p>Drowsiness, sedation, dizziness, agitation, anxiety, paresthesia, the sensation of cold,&#x000a0;pruritus, skin rash, diarrhea, gynecologic disease, urinary retention, transient&#x000a0;increase (greater than&#x000a0;2-fold) of serum aminotransferases, injection site reaction, hypoxia, fever.<xref ref-type="bibr" rid="article-38853.r34">[34]</xref></p>
        <p>5-HT3 receptor antagonists carry a risk of dose-dependent QT prolongation.<xref ref-type="bibr" rid="article-38853.r35">[35]</xref> The Food and Drug Administration (FDA) issued a warning about the risk of QT prolongation associated with a single dose of 32 mg intravenous (IV) ondansetron.<xref ref-type="bibr" rid="article-38853.r35">[35]</xref> Most published literature shows that the risk of QT prolongation with 5-HT3 antagonists is clinically insignificant in healthy patients. A review of several studies conducted on healthy patients concludes that dolasetron carries the highest risk of QT prolongation, followed by ondansetron and then granisetron.<xref ref-type="bibr" rid="article-38853.r36">[36]</xref> Further studies are needed to determine the cardiovascular safety of 5-HT3 antagonists in patients with cancer, polypharmacy, and other cardiotoxic medications.<xref ref-type="bibr" rid="article-38853.r36">[36]</xref> Experts recommend using the antiemetic agent with the least known QT prolongation, such as polanosetron, in patients at risk of QT prolongation.<xref ref-type="bibr" rid="article-38853.r3">[3]</xref></p>
        <p>
<bold>Pregnancy</bold>
</p>
        <p>5-HT3 receptor antagonists are FDA pregnancy category B. Available human studies examining early pregnancy conclude there is not a high risk of congenital malformations. There is a small increased risk of septal defects and cleft palate. Animal studies show no increased risk during early pregnancy. The presence or absence of 5-HT3 receptor antagonists in breast milk has not been established. The American Academy of Obstetrics and Gynecology (ACOG) guidelines provide a treatment algorithm for nausea and vomiting in pregnancy. Ondansetron can be added for patients who remain symptomatic despite the use of a pyridoxine/doxylamine combination along with adjunct therapy.<xref ref-type="bibr" rid="article-38853.r37">[37]</xref> In patients without dehydration, the ACOG guideline recommends oral ondansetron. In patients with dehydration receiving IV fluid replacement, the ACOG guideline recommends IV ondansetron.</p>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <p>The 5-HT3 receptor antagonists are metabolized by different isoenzymes of the cytochrome P450 (CYP450) system.<xref ref-type="bibr" rid="article-38853.r38">[38]</xref><xref ref-type="bibr" rid="article-38853.r39">[39]</xref><xref ref-type="bibr" rid="article-38853.r40">[40]</xref> Therefore, these drugs will likely interact with many prescription or over-the-counter medications and supplements. The clinical significance of the 5-HT3 drug-drug interactions is uncertain because studies are limited.<xref ref-type="bibr" rid="article-38853.r18">[18]</xref> An in-vitro study showed that ketoconazole inhibits the metabolism of granisetron.<xref ref-type="bibr" rid="article-38853.r18">[18]</xref> Granisetron does not inhibit CYP450 enzymes. Ondansetron is metabolized by CYP3A4, CYP2D6, and CYP1A2 enzymes. Therefore, medications that induce or inhibit these CYP450 isoenzymes alter the metabolism of ondansetron. However, ondansetron dosage adjustment is not recommended. Dolasetron is a prodrug activated by CYP450 enzymes in the liver.<xref ref-type="bibr" rid="article-38853.r18">[18]</xref> Drug interactions with commonly used chemotherapy drugs are not clinically significant. The manufacturer of dolasetron does not recommend dosage adjustments. The World Health Organization (WHO), the Food and Drug Administration (FDA), and Health Canada (HC) requested that manufacturers of 5-HT3 receptor antagonists include the risk of serotonin syndrome in drug labeling.<xref ref-type="bibr" rid="article-38853.r41">[41]</xref> However, there is insufficient evidence that administering 5-HT3 receptor antagonists with other serotonergic drugs contributes to the development of serotonin syndrome. The first-generation 5-HT3 receptor antagonists,&#x000a0;dolasetron, ondansetron, granisetron, and tropisetron, may cause QT prolongation.<xref ref-type="bibr" rid="article-38853.r42">[42]</xref> Palonosetron does not cause a clinically significant QT prolongation.</p>
      </sec>
      <sec id="article-38853.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>The major relative contraindications include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Hypersensitivity to 5-HT3 receptor antagonists or any formulation components due to cross-reactivity concerns.</p>
          </list-item>
          <list-item>
            <p>Concomitant use with apomorphine due to concern for a decreased level of consciousness and hypotension.<xref ref-type="bibr" rid="article-38853.r43">[43]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Box Warnings</bold>
</p>
        <p>The 5-HT3 receptor antagonist labeling includes a warning about the risk of serotonin syndrome in combination with other serotonergic drugs. However, the evidence is limited.<xref ref-type="bibr" rid="article-38853.r41">[41]</xref> The 5-HT3 receptor antagonists are associated with a varying level of QT prolongation based on the agent.<xref ref-type="bibr" rid="article-38853.r2">[2]</xref> Ondansetron ODT contains a small amount of phenylalanine. Patients with phenylketonuria cannot metabolize phenylalanine.<xref ref-type="bibr" rid="article-38853.r44">[44]</xref></p>
      </sec>
      <sec id="article-38853.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Baseline ECG for at-risk patient populations should be obtained, and sodium, potassium, calcium, and magnesium serum levels should be monitored.<xref ref-type="bibr" rid="article-38853.r45">[45]</xref></p>
        <p>
<bold>Arrhythmia</bold>
</p>
        <p>5-HT3&#x000a0;receptor antagonists have been associated with cardiac arrhythmia.<xref ref-type="bibr" rid="article-38853.r46">[46]</xref> The risk of arrhythmia with 5-HT3 receptor antagonists increases with the concomitant use of other QT-prolonging agents, intravenous route of administration, and patients with a significant medical history.<xref ref-type="bibr" rid="article-38853.r47">[47]</xref> Healthcare professionals should use 5-HT3 receptor antagonists with caution in patients with a history of congenital long QT syndrome, ventricular arrhythmias, cardiac disease, electrolyte abnormalities, or concomitant cardiotoxic chemotherapy.</p>
        <p>
<bold>Serotonin Syndrome</bold>
</p>
        <p>Evidence is insufficient to conclude that 5-HT3 receptor antagonists contribute to the development of serotonin syndrome.<xref ref-type="bibr" rid="article-38853.r41">[41]</xref> However, the World Health Organization (WHO), the US Food and Drug Administration (FDA), and Health Canada suggest a risk of serotonin syndrome by using 5-HT3 receptor antagonists in combination with other serotonergic drugs. The package inserts for the 5-HT3 receptor antagonist require healthcare professionals to monitor patients for signs of serotonin syndrome.<xref ref-type="bibr" rid="article-38853.r41">[41]</xref> Signs and symptoms include mental status changes, autonomic instability, tachycardia, labile blood pressure, diaphoresis, flushing, neuromuscular changes, GI symptoms, and seizures.<xref ref-type="bibr" rid="article-38853.r48">[48]</xref> If serotonin syndrome occurs, discontinue 5-HT3&#x000a0;receptor antagonists and initiate supportive management.</p>
        <p>
<bold>Constipation</bold>
</p>
        <p>Constipation is a commonly reported adverse effect with all formulations of 5-HT3 receptor antagonists.<xref ref-type="bibr" rid="article-38853.r49">[49]</xref> Therefore, healthcare professionals should closely monitor patients at risk of intestinal obstruction.<xref ref-type="bibr" rid="article-38853.r46">[46]</xref></p>
      </sec>
      <sec id="article-38853.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Overdose is rare, and there is no fatal dose yet established. 5-HT3 receptor antagonists have a broad therapeutic index with mild side effects that occur infrequently. There is no antidote for 5-HT3 receptor antagonists.<xref ref-type="bibr" rid="article-38853.r50">[50]</xref>&#x000a0;Therefore, the healthcare team treats patients with supportive therapy, such as IV fluid resuscitation and norepinephrine infusions. In a case report of intentional granisetron overdose, the patient presented with&#x000a0;significant hemodynamic instability, characterized by hypotension and ECG changes.<xref ref-type="bibr" rid="article-38853.r50">[50]</xref></p>
      </sec>
      <sec id="article-38853.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Nausea and vomiting can negatively impact a patient's health and quality of life, especially when induced by cancer treatment. CINV is associated with increased healthcare costs.<xref ref-type="bibr" rid="article-38853.r51">[51]</xref> An interdisciplinary team can ensure that antiemetic guidelines are appropriately followed. Physicians, physician assistants, and nurse practitioners can identify patient-specific factors that increase the risk of CINV, such as female gender, age less than 50 years, and anxiety.<xref ref-type="bibr" rid="article-38853.r52">[52]</xref> Nurses can assess patient history to anticipate nausea and vomiting and advocate to premedicate patients. Pharmacists can identify the emetogenic risk of cancer medications, identify drug interactions and adverse effects, and recommend the appropriate monitoring parameters.<xref ref-type="bibr" rid="article-38853.r53">[53]</xref> An interdisciplinary team can work together to ensure patients understand the antiemetic role of 5-HT3 receptor antagonists in preventing CINV. This will help increase adherence when the healthcare team prescribes additional doses of 5-HT3 receptor antagonists for the patient to take at home.<xref ref-type="bibr" rid="article-38853.r54">[54]</xref></p>
      </sec>
      <sec id="article-38853.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=38853&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=38853">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/38853/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=38853">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-38853.s11">
        <title>References</title>
        <ref id="article-38853.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Machu</surname>
                <given-names>TK</given-names>
              </name>
            </person-group>
            <article-title>Therapeutics of 5-HT3 receptor antagonists: current uses and future directions.</article-title>
            <source>Pharmacol Ther</source>
            <year>2011</year>
            <month>Jun</month>
            <volume>130</volume>
            <issue>3</issue>
            <fpage>338</fpage>
            <page-range>338-47</page-range>
            <pub-id pub-id-type="pmid">21356241</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38853.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tricco</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Soobiah</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Antony</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hemmelgarn</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Moher</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hutton</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Straus</surname>
                <given-names>SE</given-names>
              </name>
            </person-group>
            <article-title>Safety of serotonin (5-HT3) receptor antagonists in patients undergoing surgery and chemotherapy: protocol for a systematic review and network meta-analysis.</article-title>
            <source>Syst Rev</source>
            <year>2013</year>
            <month>Jun</month>
            <day>28</day>
            <volume>2</volume>
            <fpage>46</fpage>
            <pub-id pub-id-type="pmid">23810058</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38853.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smith</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Cox</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>EJ</given-names>
              </name>
            </person-group>
            <article-title>5-HT3 receptor antagonists for the treatment of nausea/vomiting.</article-title>
            <source>Ann Palliat Med</source>
            <year>2012</year>
            <month>Jul</month>
            <volume>1</volume>
            <issue>2</issue>
            <fpage>115</fpage>
            <page-range>115-20</page-range>
            <pub-id pub-id-type="pmid">25841471</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38853.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lummis</surname>
                <given-names>SC</given-names>
              </name>
            </person-group>
            <article-title>5-HT(3) receptors.</article-title>
            <source>J Biol Chem</source>
            <year>2012</year>
            <month>Nov</month>
            <day>23</day>
            <volume>287</volume>
            <issue>48</issue>
            <fpage>40239</fpage>
            <page-range>40239-45</page-range>
            <pub-id pub-id-type="pmid">23038271</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38853.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rapoport</surname>
                <given-names>BL</given-names>
              </name>
            </person-group>
            <article-title>Delayed Chemotherapy-Induced Nausea and Vomiting: Pathogenesis, Incidence, and Current Management.</article-title>
            <source>Front Pharmacol</source>
            <year>2017</year>
            <volume>8</volume>
            <fpage>19</fpage>
            <pub-id pub-id-type="pmid">28194109</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38853.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Navari</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Aapro</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Antiemetic Prophylaxis for Chemotherapy-Induced Nausea and Vomiting.</article-title>
            <source>N Engl J Med</source>
            <year>2016</year>
            <month>Apr</month>
            <day>07</day>
            <volume>374</volume>
            <issue>14</issue>
            <fpage>1356</fpage>
            <page-range>1356-67</page-range>
            <pub-id pub-id-type="pmid">27050207</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38853.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Navari</surname>
                <given-names>RM</given-names>
              </name>
            </person-group>
            <article-title>Treatment of Breakthrough and Refractory Chemotherapy-Induced Nausea and Vomiting.</article-title>
            <source>Biomed Res Int</source>
            <year>2015</year>
            <volume>2015</volume>
            <fpage>595894</fpage>
            <pub-id pub-id-type="pmid">26421294</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38853.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gralla</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lichinitser</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Van Der Vegt</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sleeboom</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Mezger</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Peschel</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Tonini</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Labianca</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Macciocchi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Aapro</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron.</article-title>
            <source>Ann Oncol</source>
            <year>2003</year>
            <month>Oct</month>
            <volume>14</volume>
            <issue>10</issue>
            <fpage>1570</fpage>
            <page-range>1570-7</page-range>
            <pub-id pub-id-type="pmid">14504060</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38853.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rao</surname>
                <given-names>KV</given-names>
              </name>
              <name>
                <surname>Faso</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Chemotherapy-induced nausea and vomiting: optimizing prevention and management.</article-title>
            <source>Am Health Drug Benefits</source>
            <year>2012</year>
            <month>Jul</month>
            <volume>5</volume>
            <issue>4</issue>
            <fpage>232</fpage>
            <page-range>232-40</page-range>
            <pub-id pub-id-type="pmid">24991322</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38853.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ottoboni</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Gelder</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>O'Boyle</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Biochronomer&#x02122; technology and the development of APF530, a sustained release formulation of granisetron.</article-title>
            <source>J Exp Pharmacol</source>
            <year>2014</year>
            <volume>6</volume>
            <fpage>15</fpage>
            <page-range>15-21</page-range>
            <pub-id pub-id-type="pmid">27186139</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38853.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barnes</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Calcanes</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Mosier</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Vacirca</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Malik</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>Granisetron Extended-Release Subcutaneous Injection versus Palonosetron Infusion for CINV Prevention: Cost Comparison of Unscheduled Hydration.</article-title>
            <source>Am Health Drug Benefits</source>
            <year>2021</year>
            <month>Dec</month>
            <volume>14</volume>
            <issue>4</issue>
            <fpage>133</fpage>
            <page-range>133-139</page-range>
            <pub-id pub-id-type="pmid">35261717</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38853.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Koren</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Motherisk update. Is ondansetron safe for use during pregnancy?</article-title>
            <source>Can Fam Physician</source>
            <year>2012</year>
            <month>Oct</month>
            <volume>58</volume>
            <issue>10</issue>
            <fpage>1092</fpage>
            <page-range>1092-3</page-range>
            <pub-id pub-id-type="pmid">23064917</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38853.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Anderka</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mitchell</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Louik</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Werler</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Hern&#x000e1;ndez-Diaz</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rasmussen</surname>
                <given-names>SA</given-names>
              </name>
              <collab>National Birth Defects Prevention Study</collab>
            </person-group>
            <article-title>Medications used to treat nausea and vomiting of pregnancy and the risk of selected birth defects.</article-title>
            <source>Birth Defects Res A Clin Mol Teratol</source>
            <year>2012</year>
            <month>Jan</month>
            <volume>94</volume>
            <issue>1</issue>
            <fpage>22</fpage>
            <page-range>22-30</page-range>
            <pub-id pub-id-type="pmid">22102545</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38853.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Roila</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Del Favero</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Ondansetron clinical pharmacokinetics.</article-title>
            <source>Clin Pharmacokinet</source>
            <year>1995</year>
            <month>Aug</month>
            <volume>29</volume>
            <issue>2</issue>
            <fpage>95</fpage>
            <page-range>95-109</page-range>
            <pub-id pub-id-type="pmid">7586904</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38853.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Spartinou</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nyktari</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Papaioannou</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Granisetron: a review of pharmacokinetics and clinical experience in chemotherapy induced - nausea and vomiting.</article-title>
            <source>Expert Opin Drug Metab Toxicol</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>13</volume>
            <issue>12</issue>
            <fpage>1289</fpage>
            <page-range>1289-1297</page-range>
            <pub-id pub-id-type="pmid">29057666</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38853.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Boxenbaum</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Gillespie</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Heck</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hahne</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Human dolasetron pharmacokinetics: II. Absorption and disposition following single-dose oral administration to normal male subjects.</article-title>
            <source>Biopharm Drug Dispos</source>
            <year>1993</year>
            <month>Mar</month>
            <volume>14</volume>
            <issue>2</issue>
            <fpage>131</fpage>
            <page-range>131-41</page-range>
            <pub-id pub-id-type="pmid">8453023</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38853.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Corrigan</surname>
                <given-names>BW</given-names>
              </name>
              <name>
                <surname>Nicholls</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Thakrar</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Lam</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Grosse</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Alianti</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Palmer</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>Heterogeneity in systemic availability of ondansetron and granisetron following oral administration.</article-title>
            <source>Drug Metab Dispos</source>
            <year>1999</year>
            <month>Jan</month>
            <volume>27</volume>
            <issue>1</issue>
            <fpage>110</fpage>
            <page-range>110-2</page-range>
            <pub-id pub-id-type="pmid">9884318</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38853.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Blower</surname>
                <given-names>PR</given-names>
              </name>
            </person-group>
            <article-title>5-HT3-receptor antagonists and the cytochrome P450 system: clinical implications.</article-title>
            <source>Cancer J</source>
            <year>2002</year>
            <season>Sep-Oct</season>
            <volume>8</volume>
            <issue>5</issue>
            <fpage>405</fpage>
            <page-range>405-14</page-range>
            <pub-id pub-id-type="pmid">12416899</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38853.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Zhong</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Chessari</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lanzarotti</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bernareggi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetics and safety evaluation of oral Palonosetron in Chinese healthy volunteers: A phase 1, open-label, randomized, cross-over study.</article-title>
            <source>Eur J Pharm Sci</source>
            <year>2021</year>
            <month>May</month>
            <day>01</day>
            <volume>160</volume>
            <fpage>105752</fpage>
            <pub-id pub-id-type="pmid">33581259</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38853.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Paul</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Callahan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Au</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kindler</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Yost</surname>
                <given-names>CS</given-names>
              </name>
            </person-group>
            <article-title>Antiemetics of the 5-hydroxytryptamine 3A antagonist class inhibit muscle nicotinic acetylcholine receptors.</article-title>
            <source>Anesth Analg</source>
            <year>2005</year>
            <month>Sep</month>
            <volume>101</volume>
            <issue>3</issue>
            <fpage>715</fpage>
            <page-range>715-721</page-range>
            <pub-id pub-id-type="pmid">16115980</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38853.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <collab>National Comprehensive Cancer Network (NCCN)</collab>
            <article-title>NCCN antiemesis guidelines emphasize 'delayed' emesis, new 5-HT3 inhibitors, and NK-1 blockers.</article-title>
            <source>J Support Oncol</source>
            <year>2004</year>
            <season>Jul-Aug</season>
            <volume>2</volume>
            <issue>4</issue>
            <fpage>366</fpage>
            <pub-id pub-id-type="pmid">15357520</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38853.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hargreaves</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Gunthorpe</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Lummis</surname>
                <given-names>SC</given-names>
              </name>
            </person-group>
            <article-title>Direct inhibition of 5-hydroxytryptamine3 receptors by antagonists of L-type Ca2+ channels.</article-title>
            <source>Mol Pharmacol</source>
            <year>1996</year>
            <month>Nov</month>
            <volume>50</volume>
            <issue>5</issue>
            <fpage>1284</fpage>
            <page-range>1284-94</page-range>
            <pub-id pub-id-type="pmid">8913360</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38853.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hainsworth</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Hesketh</surname>
                <given-names>PJ</given-names>
              </name>
            </person-group>
            <article-title>Single-dose ondansetron for the prevention of cisplatin-induced emesis: efficacy results.</article-title>
            <source>Semin Oncol</source>
            <year>1992</year>
            <month>Dec</month>
            <volume>19</volume>
            <issue>6 Suppl 15</issue>
            <fpage>14</fpage>
            <page-range>14-9</page-range>
            <pub-id pub-id-type="pmid">1485176</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38853.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kovac</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>O'Connor</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Pearman</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Kekoler</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Edmondson</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Baughman</surname>
                <given-names>VL</given-names>
              </name>
              <name>
                <surname>Angel</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Campbell</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Jense</surname>
                <given-names>HG</given-names>
              </name>
              <name>
                <surname>Mingus</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shahvari</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Creed</surname>
                <given-names>MR</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of repeat intravenous dosing of ondansetron in controlling postoperative nausea and vomiting: a randomized, double-blind, placebo-controlled multicenter trial.</article-title>
            <source>J Clin Anesth</source>
            <year>1999</year>
            <month>Sep</month>
            <volume>11</volume>
            <issue>6</issue>
            <fpage>453</fpage>
            <page-range>453-9</page-range>
            <pub-id pub-id-type="pmid">10526822</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38853.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Henriksson</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lomberg</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Israelsson</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Zackrisson</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Franz&#x000e9;n</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>The effect of ondansetron on radiation-induced emesis and diarrhoea.</article-title>
            <source>Acta Oncol</source>
            <year>1992</year>
            <volume>31</volume>
            <issue>7</issue>
            <fpage>767</fpage>
            <page-range>767-9</page-range>
            <pub-id pub-id-type="pmid">1476756</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38853.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lanciano</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sherman</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Michalski</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Preston</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Yocom</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Friedman</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>The efficacy and safety of once-daily Kytril (granisetron hydrochloride) tablets in the prophylaxis of nausea and emesis following fractionated upper abdominal radiotherapy.</article-title>
            <source>Cancer Invest</source>
            <year>2001</year>
            <volume>19</volume>
            <issue>8</issue>
            <fpage>763</fpage>
            <page-range>763-72</page-range>
            <pub-id pub-id-type="pmid">11768028</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38853.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mikawa</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Takao</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Nishina</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Shiga</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Maekawa</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Obara</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Optimal dose of granisetron for prophylaxis against postoperative emesis after gynecological surgery.</article-title>
            <source>Anesth Analg</source>
            <year>1997</year>
            <month>Sep</month>
            <volume>85</volume>
            <issue>3</issue>
            <fpage>652</fpage>
            <page-range>652-6</page-range>
            <pub-id pub-id-type="pmid">9296425</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38853.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shah</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>DeGroot</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Apseloff</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetic evaluation and safety profile of a 15-minute versus 30-second infusion of palonosetron in healthy subjects.</article-title>
            <source>J Clin Pharmacol</source>
            <year>2006</year>
            <month>Oct</month>
            <volume>46</volume>
            <issue>10</issue>
            <fpage>1139</fpage>
            <page-range>1139-45</page-range>
            <pub-id pub-id-type="pmid">16988202</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38853.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Ahn</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Kang</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Comparison of the Effectiveness of Palonosetron and Ramosetron in Preventing Postoperative Nausea and Vomiting: Updated Systematic Review and Meta-Analysis with Trial Sequential Analysis.</article-title>
            <source>J Pers Med</source>
            <year>2022</year>
            <month>Dec</month>
            <day>29</day>
            <volume>13</volume>
            <issue>1</issue>
            <pub-id pub-id-type="pmid">36675743</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38853.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hesketh</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Kris</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Basch</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Bohlke</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Barbour</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Clark-Snow</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Danso</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Dennis</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Dupuis</surname>
                <given-names>LL</given-names>
              </name>
              <name>
                <surname>Dusetzina</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Eng</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Feyer</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Jordan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Noonan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sparacio</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lyman</surname>
                <given-names>GH</given-names>
              </name>
            </person-group>
            <article-title>Antiemetics: ASCO Guideline Update.</article-title>
            <source>J Clin Oncol</source>
            <year>2020</year>
            <month>Aug</month>
            <day>20</day>
            <volume>38</volume>
            <issue>24</issue>
            <fpage>2782</fpage>
            <page-range>2782-2797</page-range>
            <pub-id pub-id-type="pmid">32658626</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38853.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Erick</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cox</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Mogensen</surname>
                <given-names>KM</given-names>
              </name>
            </person-group>
            <article-title>ACOG Practice Bulletin 189: Nausea and Vomiting of Pregnancy.</article-title>
            <source>Obstet Gynecol</source>
            <year>2018</year>
            <month>May</month>
            <volume>131</volume>
            <issue>5</issue>
            <fpage>935</fpage>
            <pub-id pub-id-type="pmid">29683896</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38853.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hesketh</surname>
                <given-names>PJ</given-names>
              </name>
            </person-group>
            <article-title>Comparative review of 5-HT3 receptor antagonists in the treatment of acute chemotherapy-induced nausea and vomiting.</article-title>
            <source>Cancer Invest</source>
            <year>2000</year>
            <volume>18</volume>
            <issue>2</issue>
            <fpage>163</fpage>
            <page-range>163-73</page-range>
            <pub-id pub-id-type="pmid">10705879</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38853.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Roila</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Tonato</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Basurto</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bracarda</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sassi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lupattelli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Picciafuoco</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ballatori</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Del Favero</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Ondansetron.</article-title>
            <source>Eur J Cancer</source>
            <year>1993</year>
            <volume>29A Suppl 1</volume>
            <fpage>S16</fpage>
            <page-range>S16-21</page-range>
            <pub-id pub-id-type="pmid">8427720</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38853.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Piechotta</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Adams</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Haque</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Scheckel</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kreuzberger</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Monsef</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Jordan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kuhr</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Skoetz</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta-analysis.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2021</year>
            <month>Nov</month>
            <day>16</day>
            <volume>11</volume>
            <issue>11</issue>
            <fpage>CD012775</fpage>
            <pub-id pub-id-type="pmid">34784425</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38853.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Singh</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Jain</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Panchal</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Madan</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kostojchin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sandhu</surname>
                <given-names>IS</given-names>
              </name>
              <name>
                <surname>Mittal</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bhogal</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Kolli</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Bejugam</surname>
                <given-names>VR</given-names>
              </name>
              <name>
                <surname>Chaturvedi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bhalla</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Piplani</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Ondansetron-induced QT prolongation among various age groups: a systematic review and meta-analysis.</article-title>
            <source>Egypt Heart J</source>
            <year>2023</year>
            <month>Jul</month>
            <day>03</day>
            <volume>75</volume>
            <issue>1</issue>
            <fpage>56</fpage>
            <pub-id pub-id-type="pmid">37395900</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38853.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Keefe</surname>
                <given-names>DL</given-names>
              </name>
            </person-group>
            <article-title>The cardiotoxic potential of the 5-HT(3) receptor antagonist antiemetics: is there cause for concern?</article-title>
            <source>Oncologist</source>
            <year>2002</year>
            <volume>7</volume>
            <issue>1</issue>
            <fpage>65</fpage>
            <page-range>65-72</page-range>
            <pub-id pub-id-type="pmid">11854548</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38853.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <collab>Committee on Practice Bulletins-Obstetrics</collab>
            <article-title>ACOG Practice Bulletin No. 189: Nausea And Vomiting Of Pregnancy.</article-title>
            <source>Obstet Gynecol</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>131</volume>
            <issue>1</issue>
            <fpage>e15</fpage>
            <page-range>e15-e30</page-range>
            <pub-id pub-id-type="pmid">29266076</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38853.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bloomer</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Baldwin</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Ayrton</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Clarke</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Chenery</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>Characterisation of the cytochrome P450 enzymes involved in the in vitro metabolism of granisetron.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>1994</year>
            <month>Dec</month>
            <volume>38</volume>
            <issue>6</issue>
            <fpage>557</fpage>
            <page-range>557-66</page-range>
            <pub-id pub-id-type="pmid">7888294</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38853.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sanwald</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>David</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dow</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of dolasetron. Comparison with other indole-containing 5-HT3 antagonists.</article-title>
            <source>Drug Metab Dispos</source>
            <year>1996</year>
            <month>May</month>
            <volume>24</volume>
            <issue>5</issue>
            <fpage>602</fpage>
            <page-range>602-9</page-range>
            <pub-id pub-id-type="pmid">8723743</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38853.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dixon</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Colthup</surname>
                <given-names>PV</given-names>
              </name>
              <name>
                <surname>Serabjit-Singh</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Kerr</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Boehlert</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>GR</given-names>
              </name>
              <name>
                <surname>Tarbit</surname>
                <given-names>MH</given-names>
              </name>
            </person-group>
            <article-title>Multiple forms of cytochrome P450 are involved in the metabolism of ondansetron in humans.</article-title>
            <source>Drug Metab Dispos</source>
            <year>1995</year>
            <month>Nov</month>
            <volume>23</volume>
            <issue>11</issue>
            <fpage>1225</fpage>
            <page-range>1225-30</page-range>
            <pub-id pub-id-type="pmid">8591723</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38853.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rojas-Fernandez</surname>
                <given-names>CH</given-names>
              </name>
            </person-group>
            <article-title>Can 5-HT<sub>3</sub> Antagonists Really Contribute to Serotonin Toxicity? A Call for Clarity and Pharmacological Law and Order.</article-title>
            <source>Drugs Real World Outcomes</source>
            <year>2014</year>
            <month>Dec</month>
            <volume>1</volume>
            <issue>1</issue>
            <fpage>3</fpage>
            <page-range>3-5</page-range>
            <pub-id pub-id-type="pmid">27747475</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38853.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yavas</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Dogan</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Yavas</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Araz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ata</surname>
                <given-names>OY</given-names>
              </name>
            </person-group>
            <article-title>Acute effect of palonosetron on electrocardiographic parameters in cancer patients: a prospective study.</article-title>
            <source>Support Care Cancer</source>
            <year>2012</year>
            <month>Oct</month>
            <volume>20</volume>
            <issue>10</issue>
            <fpage>2343</fpage>
            <page-range>2343-7</page-range>
            <pub-id pub-id-type="pmid">22170340</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38853.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Martirosov</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Grigor'ev</surname>
                <given-names>IuG</given-names>
              </name>
              <name>
                <surname>Zorin</surname>
                <given-names>VV</given-names>
              </name>
              <name>
                <surname>Borovkov</surname>
                <given-names>MV</given-names>
              </name>
            </person-group>
            <article-title>[Comparative experimental study of antiemetic action of latranum in radiation-induced vomiting and vomiting caused by apomorphine].</article-title>
            <source>Radiats Biol Radioecol</source>
            <year>2003</year>
            <season>Jan-Feb</season>
            <volume>43</volume>
            <issue>1</issue>
            <fpage>60</fpage>
            <page-range>60-4</page-range>
            <pub-id pub-id-type="pmid">12677660</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38853.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van Wegberg</surname>
                <given-names>AMJ</given-names>
              </name>
              <name>
                <surname>MacDonald</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ahring</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>B&#x000e9;langer-Quintana</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Blau</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Bosch</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Burlina</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Campistol</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Feillet</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Gi&#x0017c;ewska</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Huijbregts</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Kearney</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Leuzzi</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Maillot</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Muntau</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>van Rijn</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Trefz</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Walter</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>van Spronsen</surname>
                <given-names>FJ</given-names>
              </name>
            </person-group>
            <article-title>The complete European guidelines on phenylketonuria: diagnosis and treatment.</article-title>
            <source>Orphanet J Rare Dis</source>
            <year>2017</year>
            <month>Oct</month>
            <day>12</day>
            <volume>12</volume>
            <issue>1</issue>
            <fpage>162</fpage>
            <pub-id pub-id-type="pmid">29025426</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38853.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Etchegoyen</surname>
                <given-names>CV</given-names>
              </name>
              <name>
                <surname>Keller</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Mrad</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Di Girolamo</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Drug-induced QT Interval Prolongation in the Intensive Care Unit.</article-title>
            <source>Curr Clin Pharmacol</source>
            <year>2017</year>
            <volume>12</volume>
            <issue>4</issue>
            <fpage>210</fpage>
            <page-range>210-222</page-range>
            <pub-id pub-id-type="pmid">29473523</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38853.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cohen</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Shlomo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dil</surname>
                <given-names>DN</given-names>
              </name>
              <name>
                <surname>Dinavitser</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Berkovitch</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Koren</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Intestinal obstruction in pregnancy by ondansetron.</article-title>
            <source>Reprod Toxicol</source>
            <year>2014</year>
            <month>Dec</month>
            <volume>50</volume>
            <fpage>152</fpage>
            <page-range>152-3</page-range>
            <pub-id pub-id-type="pmid">25461913</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38853.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Freedman</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Uleryk</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Rumantir</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Finkelstein</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Ondansetron and the risk of cardiac arrhythmias: a systematic review and postmarketing analysis.</article-title>
            <source>Ann Emerg Med</source>
            <year>2014</year>
            <month>Jul</month>
            <volume>64</volume>
            <issue>1</issue>
            <fpage>19</fpage>
            <page-range>19-25.e6</page-range>
            <pub-id pub-id-type="pmid">24314899</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38853.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gillman</surname>
                <given-names>PK</given-names>
              </name>
            </person-group>
            <article-title>CNS toxicity involving methylene blue: the exemplar for understanding and predicting drug interactions that precipitate serotonin toxicity.</article-title>
            <source>J Psychopharmacol</source>
            <year>2011</year>
            <month>Mar</month>
            <volume>25</volume>
            <issue>3</issue>
            <fpage>429</fpage>
            <page-range>429-36</page-range>
            <pub-id pub-id-type="pmid">20142303</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38853.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Garsed</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Chernova</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hastings</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lam</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Marciani</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Henry</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hall</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Whorwell</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Spiller</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea.</article-title>
            <source>Gut</source>
            <year>2014</year>
            <month>Oct</month>
            <volume>63</volume>
            <issue>10</issue>
            <fpage>1617</fpage>
            <page-range>1617-25</page-range>
            <pub-id pub-id-type="pmid">24334242</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38853.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rochford</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kiernan</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Aziz</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Dolasetron overdose resulting in prolonged QTc interval and severe hypotension: a case report and literature review.</article-title>
            <source>Emerg Med J</source>
            <year>2007</year>
            <month>Jul</month>
            <volume>24</volume>
            <issue>7</issue>
            <fpage>515</fpage>
            <page-range>515-7</page-range>
            <pub-id pub-id-type="pmid">17582056</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38853.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Burke</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Wisniewski</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ernst</surname>
                <given-names>FR</given-names>
              </name>
            </person-group>
            <article-title>Resource utilization and costs associated with chemotherapy-induced nausea and vomiting (CINV) following highly or moderately emetogenic chemotherapy administered in the US outpatient hospital setting.</article-title>
            <source>Support Care Cancer</source>
            <year>2011</year>
            <month>Jan</month>
            <volume>19</volume>
            <issue>1</issue>
            <fpage>131</fpage>
            <page-range>131-40</page-range>
            <pub-id pub-id-type="pmid">20101417</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38853.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sekine</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Segawa</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kubota</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Saeki</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Risk factors of chemotherapy-induced nausea and vomiting: index for personalized antiemetic prophylaxis.</article-title>
            <source>Cancer Sci</source>
            <year>2013</year>
            <month>Jun</month>
            <volume>104</volume>
            <issue>6</issue>
            <fpage>711</fpage>
            <page-range>711-7</page-range>
            <pub-id pub-id-type="pmid">23480814</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38853.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McCullough</surname>
                <given-names>SW</given-names>
              </name>
            </person-group>
            <article-title>Chemotherapy-induced nausea and vomiting: roles of pharmacists and formulary decision makers.</article-title>
            <source>Am J Manag Care</source>
            <year>2017</year>
            <month>Sep</month>
            <volume>23</volume>
            <issue>14 Suppl</issue>
            <fpage>S266</fpage>
            <page-range>S266-S271</page-range>
            <pub-id pub-id-type="pmid">28978207</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38853.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smith</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cunningham</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Recent Advances in Antiemetics: New Formulations of 5-HT3 Receptor Antagonists in Adults.</article-title>
            <source>Cancer Nurs</source>
            <year>2020</year>
            <season>Jul/Aug</season>
            <volume>43</volume>
            <issue>4</issue>
            <fpage>E217</fpage>
            <page-range>E217-E228</page-range>
            <pub-id pub-id-type="pmid">30688665</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
